Q2 2025 Earnings Forecast for Incyte Co. (NASDAQ:INCY) Issued By William Blair

Incyte Co. (NASDAQ:INCY - Free Report) - William Blair decreased their Q2 2025 earnings per share (EPS) estimates for Incyte in a report released on Tuesday, April 23rd. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $1.19 per share for the quarter, down from their previous forecast of $1.23. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Incyte's current full-year earnings is $3.85 per share. William Blair also issued estimates for Incyte's Q3 2025 earnings at $1.31 EPS and Q4 2025 earnings at $1.35 EPS.

Several other research analysts have also recently issued reports on the company. BMO Capital Markets increased their price objective on Incyte from $58.00 to $64.00 and gave the stock a "market perform" rating in a research report on Wednesday, February 14th. Bank of America lowered their target price on Incyte from $69.00 to $67.00 and set a "neutral" rating on the stock in a report on Wednesday, March 13th. Stifel Nicolaus upped their target price on Incyte from $67.00 to $68.00 and gave the company a "hold" rating in a report on Wednesday, February 14th. Royal Bank of Canada reissued a "sector perform" rating and issued a $65.00 target price on shares of Incyte in a report on Monday, March 25th. Finally, JMP Securities lowered Incyte from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 14th. Nine research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $75.50.

Incyte Price Performance

NASDAQ:INCY traded up $0.09 during trading hours on Wednesday, hitting $51.74. The company's stock had a trading volume of 1,564,434 shares, compared to its average volume of 1,724,911. The business's 50-day moving average is $57.06 and its two-hundred day moving average is $57.78. The company has a market capitalization of $11.62 billion, a PE ratio of 19.52, a PEG ratio of 1.20 and a beta of 0.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.36 and a current ratio of 3.55. Incyte has a 52-week low of $50.27 and a 52-week high of $75.74.

Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.09). The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Incyte had a return on equity of 12.56% and a net margin of 16.17%. Incyte's revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.44 EPS.

Hedge Funds Weigh In On Incyte

A number of large investors have recently modified their holdings of the company. Cape Investment Advisory Inc. purchased a new stake in Incyte during the 4th quarter worth approximately $25,000. Larson Financial Group LLC grew its position in shares of Incyte by 4,220.0% in the 4th quarter. Larson Financial Group LLC now owns 432 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 422 shares in the last quarter. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Incyte in the 4th quarter worth approximately $31,000. Redmont Wealth Advisors LLC acquired a new position in shares of Incyte in the 1st quarter worth approximately $28,000. Finally, Riverview Trust Co acquired a new position in shares of Incyte in the 1st quarter worth approximately $29,000. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.